No abstract available.
Acneiform Eruptions ; Bevacizumab

BACKGROUND: Drug eruptions are common in hospitalized patients. Rapid and accurate diagnosis is essential but often difficult. OBJECTIVE: This study defined the clinical features and causative drugs among inpatients presenting with drug eruptions. METHODS: We retrospectively analyzed the clinical and laboratory data of inpatients who sought consultations with the Dermatology Department for a diagnosis of drug eruptions. RESULTS: A total of 228 patients were diagnosed with drug eruptions, and this study included 139 patients. The highest incidence of drug eruptions was observed in patients in their 50s (22.3%). The most common latent period was up to 1 week (57.6%). The most common drug eruptions were exanthematous eruptions (59.7%), acneiform eruptions (10.8%), and urticaria (9.3%). The most common causative drugs were antibiotics (53.2%), followed by anticancer drugs (19.4%), and contrast media (6.5%). Laboratory abnormalities included eosinophilia (15.8%), abnormal liver function tests (7.9%), leukopenia (4.3%), an elevated serum creatinine level (2.2%), and leukocytosis (0.7%). CONCLUSION: In descending order, the most frequent drug eruptions were exanthematous eruptions, acneiform eruptions, and urticaria, and the most common causative drugs were antibiotics, anticancer agents, and contrast media. Prompt diagnosis and discontinuation of the causative drug are important in this context. Clinicians should be aware of cutaneous adverse drug reactions.
Acneiform Eruptions ; Anti-Bacterial Agents ; Antineoplastic Agents ; Contrast Media ; Creatinine ; Dermatology* ; Diagnosis ; Drug Eruptions* ; Drug-Related Side Effects and Adverse Reactions ; Eosinophilia ; Humans ; Incidence ; Inpatients* ; Leukocytosis ; Leukopenia ; Liver Function Tests ; Referral and Consultation ; Retrospective Studies ; Urticaria

No abstract available.
Acneiform Eruptions* ; Dasatinib* ; Drug Eruptions ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive* ; Pleural Effusion*

BACKGROUND: A number of anticancer agents are known to induce many adverse reactions in the skin. Related cutaneous adverse drug reactions influence the morbidity, mortality, and anti-cancer regimen of the patients. A multidisciplinary approach to cancer management has been emphasized. OBJECTIVE: To identify the causative anticancer agents and frequency of adverse reactions in the skin. METHODS: We retrospectively reviewed the medical records of patients who consulted at the Dermatology Department of Busan Paik Hospital and Haeundae Paik Hospital from January 2013 to February 2015. RESULTS: A total of 140 patients were enrolled. Among the 45 patients treated with antimetabolite analogs (30 cytarabine, 7 gemcitabine, 3 methotrexate, 2 fludarabine, 2 doxifluridine, and 1 decitabine), exanthematous drug eruption (49.1%) was the most common reaction, followed by hand-foot syndrome (28.3%). Among the 35 patients treated with fluorouracil (22 5-fluorouracil and 13 capecitabine), hand-foot syndrome (47.2%) was the most common, followed by acneiform eruption (25.0%). Among the 24 patients treated with epidermal grow factor receptor inhibitors (10 erlotinib, 10 cetuximab, and 4 gefitinib), acneiform eruption (54.8%) was the most common, followed by xerosis (19.4%). Among the 11 patients treated with anthracyclines (9 doxorubicin, 1 daunorubicin, and 1 idarubicin), acneiform eruption (45.5%) was the most common, followed by hand-foot syndrome (36.4%). Among the 7 patients treated with taxanes (4 docetaxel and 3 paclitaxel), hand-foot syndrome (42.8%) was the most common. Among the 6 patients treated with angiogenesis-inducing inhibitors (3 sorafenib, 2 pazopanib, and 1 sunitinib), hand-foot skin reaction (66.7%) was the most common. Only 2 patients (1.4%) changed treatments due to intolerable skin reactions. CONCLUSION: Clinicians should be aware of the various skin reactions of anticancer agents and predict their clinical course effectively.
Acneiform Eruptions ; Anthracyclines ; Antineoplastic Agents ; Busan ; Cetuximab ; Cytarabine ; Daunorubicin ; Dermatology ; Doxorubicin ; Drug Eruptions ; Drug-Related Side Effects and Adverse Reactions ; Erlotinib Hydrochloride ; Fluorouracil ; Hand-Foot Syndrome ; Humans ; Medical Records ; Methotrexate ; Mortality ; Retrospective Studies* ; Skin ; Taxoids

Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Acneiform Eruptions* ; Carcinoma, Non-Small-Cell Lung ; Clindamycin ; Dermatology ; Drug Therapy ; Epidermal Growth Factor ; Humans ; Minocycline ; Skin

Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Acneiform Eruptions* ; Carcinoma, Non-Small-Cell Lung ; Clindamycin ; Dermatology ; Drug Therapy ; Epidermal Growth Factor ; Humans ; Minocycline ; Skin

No abstract available.
Acneiform Eruptions*

Pityrosporum folliculitis (PF) is a polymorphic dermatomycosis characterized by the development of multiple follicular papules and pustules. This disease occurs mainly in the seborrheic areas of the face, back and chest. Being aggravated by hot weather and sweating, PF has shown to be a common disease in the tropics. Clinically, it may present similarly as other diseases such as acneiform drug eruption. Differentiation between these two disease entities and an objective method of ruling out PF are important in our setting as management will differ. We report a case of pityrosporum folliculitis in a patient who had a history of chronic oral steroid intake and presented clinically with an acneiform eruption on his face, chest and back. Microscopy and skin biopsy revealed the presence of Pityrosporum. The patient was successfully treated with systemic and topical anti-fungal medications. We postulate that in this patient, immunosuppression due to exogenous steroids may be the predisposing factor for pityrosporum folliculitis. Since acneiform drug eruption and pityrosporum folliculitis may present similarly, misdiagnosis is common. We suggest that when presented with an acneiform eruption in an immunosuppressed patient, direct microscopy of KOH mounts of lower comedonal

Human ; Male ; Adult ; Acneiform Eruptions ; Biopsy ; Causality ; Dermatomycoses ; Diagnostic Errors ; Drug Eruptions ; Folliculitis ; Malassezia ; Skin ; Sweating ; Weather

Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.
Acneiform Eruptions ; Alopecia ; Carcinoma, Non-Small-Cell Lung ; Dermatitis, Seborrheic ; Female ; Hair ; Humans ; Middle Aged ; Paronychia ; Protein-Tyrosine Kinases ; Quinazolines ; Receptor, Epidermal Growth Factor ; Skin ; Erlotinib Hydrochloride

BACKGROUND: Fractional photothermolysis makes thousands of minute areas called microthermal treatment zones on the skin surface and transmits thermal injury to facilitate heat shock protein formation around the dermis. Potential side effects include acneiform eruption, herpes simplex virus outbreak, erythema, and post-inflammatory hyperpigmentation. OBJECTIVE: To investigate and compare the changes in the skin of Asian patients after two different fractional photothermolysis systems (FPS) on a split face. METHODS: A half-split face study was performed with 10,600 nm carbon dioxide FPS on the left and 1,550 nm erbium-doped FPS on the right side of the face. Only one session of laser irradiation and several biophysical measurements were done. RESULTS: Although both FPS proved to be effective in treating acne scar and wrinkle patients, a slightly higher satisfaction rating was seen with the 10,600 nm FPS treatment. Both types of FPS showed a significant increase in transepidermal water loss which decreased gradually after treatment and returned to pre-treatment level after 1 week. A decreased reviscometer score was sustained for a longer period in wrinkle areas treated with 10,600 nm FPS. CONCLUSION: Even though the changes in skin varied according to different FPS wave-length, adverse outcomes, such as increased erythema and TEWL were entirely subdued within 3 months of treatment.
Acne Vulgaris ; Acneiform Eruptions ; Asian Continental Ancestry Group ; Carbon Dioxide ; Cicatrix ; Dermis ; Erythema ; Heat-Shock Proteins ; Humans ; Methylmethacrylates ; Polystyrenes ; Simplexvirus ; Skin ; Water Loss, Insensible